Micro- and nanotechnological delivery platforms for treatment of dysbiosis-related inflammatory bowel disease

References

• 1. Corridoni D, Arseneau KO, Cominelli F. Inflammatory bowel disease. Immunol. Lett. 161(2), 231–235 (2014).
  Medline CASGoogle Scholar
• 2. Melmed GY, Targan SR. Future biologic targets for IBD: potentials and pitfalls. Nat. Rev. Gastro. Hepat. 7(2), 110–117 (2010).
  MedlineGoogle Scholar
• 3. D'Haens GR, Panaccione R, Higgins PDR et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: When to start, when to stop, which drug to choose, and how to predict response? Am. J. Gastroenterol. 106(2), 199–212 (2011).
  MedlineGoogle Scholar
• 4. Forbes JD, Van Domselaar G, Bernstein CN. The gut microbiota in immune-mediated inflammatory diseases. Front. Microbiol. 7, 1081 (2016).
  MedlineGoogle Scholar
• 5. Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 152(2), 327–339 (2017).
  Medline CASGoogle Scholar
• 6. Sussman D, Santaolalla R, Strobel S, Dheer R, Abreu MT. Cancer in inflammatory bowel disease: lessons from animal models. Curr. Opin. Gastroenterol. 28(4), 327 (2012).
  Medline CASGoogle Scholar
• 7. Khan KJ, Ullman TA, Ford AC et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 106(4), 661–673 (2011).
  Medline CASGoogle Scholar
• 8. Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp. Ther. Med. 4(6), 1051–1056 (2012).
  Medline CASGoogle Scholar
• 9. Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases. Am. J. Gastroenterol. Suppl. 1(1), 15–21 (2012).
  CASGoogle Scholar
• 10. Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science 308(5728), 1635–1638 (2005).
  MedlineGoogle Scholar
• 11. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 157(1), 121–141 (2014).
  Medline CASGoogle Scholar
• 12. Frank DN, Amand ALS, Feldman RA et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 104(34), 13780–13785 (2007).
  Medline CASGoogle Scholar
• 13. Papa E, Docktor M, Smillie C et al. Noninvasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS ONE 7(6), e39242 (2012).
  Medline CASGoogle Scholar
• 14. Newman KM, Vaughn BP. Efficacy of intestinal microbiota transplantation in ulcerative colitis: a review of current literature and knowledge. Minerva Gastroenterol. Dietol. 65(4), 268–279 (2019).
  MedlineGoogle Scholar
• 15. Choi HH, Cho YS. Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin. Endosc. 49(3), 257 (2016).
  MedlineGoogle Scholar
• 16. Yeung TW, Üçok EF, Tiani KA, McClements DJ, Sela DA. Microencapsulation in alginate and chitosan microgels to enhance viability of Bifidobacterium longum for oral delivery. Front. Microbiol. 7, 494 (2016).
  MedlineGoogle Scholar
• 17. Ding WK, Shah NP. Effect of various encapsulating materials on the stability of probiotic bacteria. J. Food Sci. 74(2), M100–M107 (2009).
  Medline CASGoogle Scholar
• 18. Teng Y, Ren Y, Sayed M et al. Plant-derived exosomal microRNAs shape the gut microbiota. Cell Host Microbe 24(5), 637–652 (2018).
  Medline CASGoogle Scholar
• 19. Liu S, da Cunha AP, Rezende RM et al. The host shapes the gut microbiota via fecal microRNA. Cell Host Microbe 19(1), 32–43 (2016).
  Medline CASGoogle Scholar
• 20. Tomkovich S, Gharaibeh RZ, Dejea CM et al. Human colon mucosal biofilms and murine host communicate via altered mRNA and microRNA expression during cancer. mSystems 5(1), e00451–19 (2020).
  Medline CASGoogle Scholar
• 21. Qiu K, Durham PG, Anselmo AC. Inorganic nanoparticles and the microbiome. Nano Res. 11(10), 4936–4954 (2018).
  CASGoogle Scholar
• 22. Ghebretatios M, Schaly S, Prakash S. Nanoparticles in the food industry and their impact on human gut microbiome and diseases. Int. J. Mol. Sci. 22(4), 1942 (2021).
  Medline CASGoogle Scholar
• 23. Pluznick JL, Protzko RJ, Gevorgyan H et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc. Natl Acad. Sci. USA 110(11), 4410–4415 (2013).
  Medline CASGoogle Scholar
• 24. Hsiao EY, McBride SW, Hsien S et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155(7), 1451–1463 (2013).
  Medline CASGoogle Scholar
• 25. Johnson SR, Lange BM. Open-access metabolomics databases for natural product research: present capabilities and future potential. Front. Bioeng. Biotechnol. 3, 22 (2015).
  MedlineGoogle Scholar
• 26. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug Discov. 15(7), 473 (2016).
  Medline CASGoogle Scholar
• 27. Bernstein CN, Fried M, Krabshuis JH et al. World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm. Bowel Dis. 16(1), 112–124 (2010).
  MedlineGoogle Scholar
• 28. Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract. Res. Clin. Gastroenterol. 24(2), 167–182 (2010).
  Medline CASGoogle Scholar
• 29. Gou S, Huang Y, Wan Y et al. Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis. Biomaterials 212, 39–54 (2019).
  Medline CASGoogle Scholar
• 30. Li C, Zhao Y, Cheng J et al. A proresolving peptide nanotherapy for site-specific treatment of inflammatory bowel disease by regulating proinflammatory microenvironment and gut microbiota. Adv. Sci. 6(18), 1900610 (2019).
  CASGoogle Scholar
• 31. Lee Y, Sugihara K, Gillilland MG et al. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat. Mater. 19(1), 118–126 (2020).
  Medline CASGoogle Scholar